The latest price target for Cytek Biosciences (NASDAQ:CTKB) was reported by Piper Sandler on November 11, 2024. The analyst firm set a price target for $8.50 expecting CTKB to rise to within 12 months (a possible 42.86% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Cytek Biosciences (NASDAQ:CTKB) was provided by Piper Sandler, and Cytek Biosciences maintained their overweight rating.

There is no last upgrade for Cytek Biosciences

There is no last downgrade for Cytek Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $8.00 to $8.50. The current price Cytek Biosciences (CTKB) is trading at is $5.95, which is out of the analyst’s predicted range.